Helix BioPharma Corp. Reports 2026 Interim Financial Results, Highlights Progress in Financing and Development
VANCOUVER, BRITISH COLUMBIA – June 12, 2026 – Leads & Copy – Helix BioPharma Corp., a clinical-stage oncology company, announced its financial results for the three- and nine-month periods ended April 30, 2026, along with the filing of its unaudited interim financial statements and related management’s discussion and analysis. The company reported a net and total comprehensive loss from operations of $671,000 for the three months ended April 30, 2026, and a loss of $2,374,000 for the nine months ended April 30, 2026. This compares to a net loss of $1,544,000 and $4,255,000 for the corresponding periods in 2025.
The reduction in net loss was attributed to decreased research and development expenses and the conclusion of the LDOS006 clinical study. These savings were partially offset by an increase in operating, general, and administrative expenses, including costs related to accounting, tax, legal, and consulting services.
Loss per common share for the reporting period was $0.01 for the three months and $0.03 for the nine months ended April 30, 2026. This is an improvement from the $0.03 and $0.08 per common share loss reported for the same periods in the previous year.
As of April 30, 2026, Helix BioPharma Corp. reported cash reserves of $2,842,000, a significant increase from $65,000 as of July 31, 2025. This boost in liquidity was largely due to proceeds from a private placement of unsecured convertible debentures.
During the quarter, the company received $3,673,000 in cash proceeds from this private placement. The convertible debentures, totaling $3,673,000, were issued subsequent to the quarter-end. They carry an annual interest rate of 25% and mature 14 months from the closing date, on July 27, 2027. The principal amount is convertible into common shares at $1.42 per share. Accrued interest is convertible at the greater of $1.42 or the 5-day volume-weighted average price less the Toronto Stock Exchange-permitted discount. As of April 30, 2026, the debentures had not yet been formally issued, and the proceeds were recorded as subscription advances, classified as a current liability.
Helix BioPharma Corp. continues to explore various financing and capital market alternatives to support its ongoing operations and future growth. The company is working with legal counsel on a base shelf prospectus filing and is in discussions with potential investment banking partners for future financing opportunities. Furthermore, Helix is evaluating strategies to broaden its investor base and enhance access to U.S. capital markets, including the possibility of a future listing on a U.S. securities exchange.
The company’s pipeline is focused on difficult-to-treat cancers. Its lead candidate, Tumor Defense Breaker™ L-DOS47, is a clinical-stage antibody-enzyme conjugate designed to improve the sensitivity of CEACAM6-expressing tumors to therapy and to enhance the efficacy of existing anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC). Helix is also developing two pre-Investigational New Drug (IND) candidates: LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, an oral gemcitabine prodrug designed for advanced cancers.
The Interim Filings, providing comprehensive details on the financial results and company operations, are available on SEDAR+ at www.sedarplus.ca and on the company’s website at https://www.helixbiopharma.com/filings-and-financials/. Helix BioPharma Corp. is listed on the TSX under the symbol HBP, on OTC PINK as HBPCD, and on the FWB exchange as HBP0.
Source: Helix BioPharma Corp.
Share this story:
